|Home | Mail | Jobs | Area Profiles | Bizstay|
|News | Property | Business | Farms | Hotels | Land | Investment|
R1.6bn Plant for Gauteng| News by Staff Reporter
SA is to build a R1.6bn pharmaceutical plant in Gauteng
Plans to build a R1.6-billion pharmaceutical plant in South Africa are underway as government seeks to locally produce the ingredients for Anti-Retroviral medication.
It was announced on Friday that government, through Pelchem (Pty) Ltd, in a joint venture together with Lonza Ltd, sought to build a R1.6-billion pharmaceutical plant in the Gauteng Province in an area near Pelindaba.
“This joint venture, named 'Ketlaphela', will establish the first pharmaceutical plant to manufacture active pharmaceutical ingredients (APIs) for antiretroviral medicines in South Africa,” said Naledi Pandor, Minister of Science.
Ketlaphela means “I will live or survive” in Sesotho.
The new company would be funded by a R1-billion capital investment by various state institutions, more than half a billion by Lonza, and R100-million from Pelchem, with total investment coming to R1.6-billion.
“Our partnership with Lonza is based on the fact that Lonza is one of the world’s leading suppliers of various products of pharmaceutical, healthcare and life sciences industries and is a global leader in the production and support of APIs in cell-based research, endotoxin detection, and cell therapy manufacturing,” said Pandor.
“Lonza’s high Swiss standards plus their superb track record of establishing and maintaining successful commercial operations in developing countries, make them a valuable and desirable partner,” he added.